Literature DB >> 35869701

COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.

Albert Gil-Vila1, Naveen Ravichandran2, Albert Selva-O'Callaghan1, Parikshit Sen3, Arvind Nune4, Prithvi Sanjeevkumar Gaur5, Raquel Arànega Gonzalez6, James B Lilleker7,8, Mrudula Joshi9, Vishwesh Agarwal10, Sinan Kardes11, Minchul Kim12, Jessica Day13,14,15, Ashima Makol16, Marcin Milchert17, Tamer Gheita18, Babur Salim19, Tsvetelina Velikova20, Abraham Edgar Gracia-Ramos21, Ioannis Parodis22,23, Elena Nikiphorou24,25, Ai Lyn Tan26,27, Tulika Chatterjee12, Lorenzo Cavagna28,29, Miguel A Saavedra30, Samuel Katsuyuki Shinjo31, Nelly Ziade32,33, Johannes Knitza34, Masataka Kuwana35, Oliver Distler36, Hector Chinoy7,37,38, Vikas Agarwal2, Rohit Aggarwal39, Latika Gupta2,7,40,41.   

Abstract

INTRODUCTION/AIMS: In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).
METHODS: Seven-day vaccine ADEs were collected in an international patient self-reported e-survey. Descriptive statistics were obtained and multivariable regression was performed.
RESULTS: Ten thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30-455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04-7.3) and minor (OR, 1.5; IQR, 1.1-2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2-4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1-3.3; and OR, 2.2; IQR, 1.1-4.3, respectively). Overall, ADEs were less frequent in inclusion-body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients. DISCUSSION: Seven-day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID-19 through vaccination likely outweighs the risk of vaccine-related ADEs. Our results may inform future guidelines regarding COVID-19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long-term outcomes and disease flares are needed to shed more light on developing future COVID-19 vaccination guidelines.
© 2022 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; dermatomyositis; myositis; rheumatology; vaccination

Mesh:

Substances:

Year:  2022        PMID: 35869701      PMCID: PMC9349921          DOI: 10.1002/mus.27681

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.852


  22 in total

1.  The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.

Authors:  David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

2.  Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.

Authors:  Ulf M Geisen; Dennis K Berner; Florian Tran; Melike Sümbül; Lena Vullriede; Maria Ciripoi; Hayley M Reid; Annika Schaffarzyk; Ann C Longardt; Jeanette Franzenburg; Paula Hoff; Jan H Schirmer; Rainald Zeuner; Anette Friedrichs; Andrea Steinbach; Christine Knies; Robert Dh Markewitz; Peter J Morrison; Sascha Gerdes; Stefan Schreiber; Bimba F Hoyer
Journal:  Ann Rheum Dis       Date:  2021-03-24       Impact factor: 19.103

3.  COVID-19 vaccination and antirheumatic therapy.

Authors:  Jack Arnold; Kevin Winthrop; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

4.  COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis.

Authors:  Haig Pakhchanian; Ahmad Saud; Rahul Raiker; Sinan Kardes; Rohit Aggarwal; Latika Gupta
Journal:  Clin Rheumatol       Date:  2022-01-27       Impact factor: 3.650

5.  Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Authors:  Sebastian Eduardo Sattui; Jean W Liew; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco Ugarte-Gil; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider
Journal:  RMD Open       Date:  2021-09

6.  COVID-19 vaccination in autoimmune disease (COVAD) survey protocol.

Authors:  Parikshit Sen; Latika Gupta; James B Lilleker; Vishwesh Aggarwal; Sinan Kardes; Marcin Milchert; Tamer Gheita; Babur Salim; Tsvetelina Velikova; Abraham Edgar Gracia-Ramos; Ioannis Parodis; Albert Selva O'Callaghan; Elena Nikiphorou; Ai Lyn Tan; Lorenzo Cavagna; Miguel A Saavedra; Samuel Katsuyuki Shinjo; Nelly Ziade; Johannes Knitza; Masataka Kuwana; Giovanni Cagnotto; Arvind Nune; Oliver Distler; Hector Chinoy; Vikas Aggarwal; Rohit Aggarwal
Journal:  Rheumatol Int       Date:  2021-11-15       Impact factor: 2.631

7.  Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.

Authors:  Samuel K Shinjo; Fernando H C de Souza; Isabela B P Borges; Alexandre M Dos Santos; Renata Miossi; Rafael G Misse; Ana C Medeiros-Ribeiro; Carla G S Saad; Emily F N Yuki; Sandra G Pasoto; Léonard V K Kupa; Carina Ceneviva; Júlia C Seraphim; Tatiana N Pedrosa; Margarete B G Vendramini; Clóvis A Silva; Nádia E Aikawa; Eloisa Bonfá
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

8.  Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines.

Authors:  Yong Fan; Yan Geng; Yu Wang; Xuerong Deng; Guangtao Li; Juan Zhao; Lanlan Ji; Xiaohui Zhang; Zhibo Song; Haoze Zhang; Xiaoying Sun; Dai Gao; Wenhui Xie; Hong Huang; YanJie Hao; Zhuoli Zhang
Journal:  Ann Rheum Dis       Date:  2021-11-25       Impact factor: 19.103

9.  Adverse events after first COVID-19 vaccination in patients with autoimmune diseases.

Authors:  Laura Boekel; Laura Y Kummer; Koos P J van Dam; Femke Hooijberg; Zoé van Kempen; Erik H Vogelzang; Luuk Wieske; Filip Eftimov; Ronald van Vollenhoven; Taco W Kuijpers; S Marieke van Ham; Sander W Tas; Joep Killestein; Maarten Boers; Mike T Nurmohamed; Theo Rispens; Gertjan Wolbink
Journal:  Lancet Rheumatol       Date:  2021-06-18

10.  Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).

Authors:  Gunther Eysenbach
Journal:  J Med Internet Res       Date:  2004-09-29       Impact factor: 5.428

View more
  1 in total

1.  COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.

Authors:  Albert Gil-Vila; Naveen Ravichandran; Albert Selva-O'Callaghan; Parikshit Sen; Arvind Nune; Prithvi Sanjeevkumar Gaur; Raquel Arànega Gonzalez; James B Lilleker; Mrudula Joshi; Vishwesh Agarwal; Sinan Kardes; Minchul Kim; Jessica Day; Ashima Makol; Marcin Milchert; Tamer Gheita; Babur Salim; Tsvetelina Velikova; Abraham Edgar Gracia-Ramos; Ioannis Parodis; Elena Nikiphorou; Ai Lyn Tan; Tulika Chatterjee; Lorenzo Cavagna; Miguel A Saavedra; Samuel Katsuyuki Shinjo; Nelly Ziade; Johannes Knitza; Masataka Kuwana; Oliver Distler; Hector Chinoy; Vikas Agarwal; Rohit Aggarwal; Latika Gupta
Journal:  Muscle Nerve       Date:  2022-08-08       Impact factor: 3.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.